Treos Bio Phase Ii Clinical Trial Mss Colorectal Cancer

TREOS Bio Partners with Charité Berlin and Junshi Biosciences to Launch Pivotal Phase II Clinical Trial in Refractory MSS Colorectal Cancer

August 27, 2025

LONDON, Aug. 27, 2025 (GLOBE NEWSWIRE) — TREOS Bio Ltd., a clinical-stage biotechnology company developing next-generation off-the-shelf peptide cancer immunotherapies, today announced the execution of…

Latest News

Treos Bio Phase Ii Clinical Trial Mss Colorectal Cancer

TREOS Bio Partners with Charité Berlin and Junshi Biosciences to Launch Pivotal Phase II Clinical Trial in Refractory MSS Colorectal Cancer

August 27, 2025

Vaxxas Hd Map A90m Funding

Vaxxas secures ~A$90 million in funding to commercialise needle-free vaccination delivery technology

August 25, 2025

Doron Therapeutics Positive Phase 2 End Of Phase Meeting 2025

Doron Therapeutics Announces Positive End-of-Phase 2 and Initial RMAT Meeting With FDA for MOTYS (PTP-001) in the Treatment of Knee Osteoarthritis

May 20, 2025

Azalea Vision 9m Series A Intelligent Connected Vision Platform

Azalea Vision Raises €9 Million in First Closing of Series A to Further Develop Intelligent Connected Vision Platform

April 30, 2025

Cadwell Seer Investment Epilepsy Diagnostics 2025

Cadwell Makes a Strategic Investment in Seer Medical to Expand Home-Based Epilepsy Diagnostics

April 16, 2025

Sprim Oneim 300m Joint Venture Clinical Trial Financing 2025

R&D SERVICES/CRO

SPRIM Global Investments and OneIM Announce $300mn Joint Venture to Accelerate Clinical Trial Financing

March 11, 2025

Pulsesight Series A Financing Pst 611 Dry Amd 2025 1

PulseSight Therapeutics Announces First Close of its Series A Financing to Fund Clinical Development of PST-611 in dry AMD

February 13, 2025

Obviohealth Obviogo 2.2 Ai Driven Study Management 2025

DIGITAL CLINICAL SOLUTION

ObvioHealth Introduces ObvioGo 2.2: Transforming Study Management with AI-Driven Innovation

January 17, 2025

Rheumagen Series A Financing Hla Gene Editing Therapies 2024 1

RheumaGen, Inc. Launches with $15 Million Series A Financing to Advance a New Class of HLA Gene-Editing Therapies for Major Autoimmune Diseases

January 9, 2025

Cilcare Completes 40m Series A

Cilcare completes a €40M series A

December 5, 2024

Doron Therapeutics 11m Series A Osteoporosis Drug Phase 3 Clinical Study

Doron Therapeutics Raises $11M Series A to Progress Biologic Regenerative Osteoarthritis Drug into Phase 3 Clinical Studies

November 25, 2024

Napo Therapeutics Best Pharmaceuticals Innovator Europe 2024

Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year – Europe”

November 19, 2024

Obviohealth Richard Watkins Chief Revenue Officer Transformation

ObvioHealth Welcomes Richard Watkins as Chief Revenue Officer at a Pivotal Moment of Transformation

October 16, 2024

Obviohealth Appointment Nicholas Campbell 2024

DIGITAL CLINICAL SOLUTION

ObvioHealth Announces the Appointment of Nicholas Campbell to Its Board of Directors

October 10, 2024

Pulsesight Therapeutics Presents Pst 611 Ever Congress 2024

PulseSight Therapeutics to Present Data on PST-611 at EVER Congress 2024

October 7, 2024

Novel Validated Approach Monitoring Infant Growth Home Clinical Trials

R&D SERVICES/CRO

SPRIM PRO Announces a Novel and Validated Approach for Monitoring Infant Growth from Home in Clinical Trials, Reducing Burdens on Caregivers and Clinical Sites

September 24, 2024

Obviohealth Strategic Investment By Guardant Health

DIGITAL CLINICAL SOLUTION

ObvioHealth announces strategic investment by Guardant Health to accelerate deployment of oncology clinical trials globally

July 29, 2024

Mimi Tang Prota Therapeutics Forbes Australia

Forbes Australia recognizes Prota Therapeutics for making waves in Australia’s startup scene at the moment

June 24, 2024

Biosenic On Its Way To Find The Necessary Funds To Perform Its Key Clinical Trial On Chronic Graft Versus Host Disease

Prota Therapeutics US $21 Million Financing Led by SPRIM Global Investments

January 16, 2024

Spexis Provides Update Regarding Debt Restructuring Moratorium

Stalicla Secures $17.4 Million in Series B Financing

January 16, 2024

Regask Welcomes New Chief Product & Technology Officer

DIGITAL CLINICAL SOLUTION

RegASK Welcomes New Chief Product & Technology Officer

November 2, 2023

Obviohealth Strengthens Leadership Team With Key Industry Appointments

DIGITAL CLINICAL SOLUTION

ObvioHealth Strengthens Leadership Team with Key Industry Appointments

October 17, 2023

Fibronostics Announces Partnership With Stone Diagnostics

Fibronostics Announces Partnership with Stone Diagnostics

October 10, 2023

Spexis Provides Business Update And Announces Financial Results For The First Half Of 2023

Spexis provides business update and announces financial results for the first half of 2023

September 29, 2023

Spexis Announces Usd $2.5 Million Capital Commitment To Support The Upcoming Phase 3 Colifin® Studies

Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies

August 14, 2023

Readout Ai Secures Pre Seed Funding To Decrease The Time From Clinical Trial Data To Clinical Trial Insight

DIGITAL CLINICAL SOLUTION

Readout AI Secures Pre-Seed Funding to Decrease the Time from Clinical Trial Data to Clinical Trial Insight

July 14, 2023

Sprim Global Investments Pte. Ltd. Completes Equity Investment In Uk Specialist Clinical Trial Site, Vctc Ltd.

DIGITAL CLINICAL SOLUTION

SPRIM Global Investments Pte. Ltd. completes equity investment in UK specialist clinical trial site, VCTC Ltd.

May 26, 2023

Obviohealth Signs R&d Partnership With A Star To Identify And Develop Novel Digital Biomarkers

DIGITAL CLINICAL SOLUTION

ObvioHealth Signs R&D Partnership with A*STAR to Identify and Develop Novel Digital Biomarkers

May 3, 2023

Spexis Announces Closing Of Capital Commitment Of Usd 4.5 Million From Sprim Global Investments (sgi) To Enable Initiation Of Colifin® Phase 3 Study

Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study

April 18, 2023

Data Vantage | Aum Biosciences, Scg Cell Therapy, Blood And Hello Health Disclose Updates

AUM Biosciences, SCG Cell Therapy, Blood And Hello Health Disclose Updates

April 6, 2023

This site uses cookies to offer you a better browsing experience. By browsing this website, you agree to our use of cookies.

Accept